Cited by 134Bariatric Surgery and OutcomesCancer Risks and FactorsEsophageal Cancer Research and Treatment

Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study

Open access
Anveden, Åsa, Taube, Magdalena, Peltonen, Markku, Jacobson, Peter, Andersson-Assarsson, Johanna C., Sjöholm, Kajsa, Svensson, Per-Arne, Carlsson, Lena M.S.·2017·Gynecologic Oncology

Abstract

Objective To examine the long-term effects of bariatric surgery on female-specific cancer in women with obesity.Methods The prospective, matched Swedish Obese Subjects (SOS) study was designed to examine outcomes after bariatric surgery. This study includes 1420 women from the SOS cohort that underwent bariatric surgery and 1447 contemporaneously matched controls who received conventional obesity treatment. Age was 37-60years and BMI was ≥38kg/m 2. Information on cancer events was obtained from the Swedish National Cancer Registry. Median follow-up time was 18.1years (interquartile range 14.8-20.9years, maximum 26years). This study is registered with ClinicalTrials.gov, NCT01479452.Results Bariatric surgery was associated with reduced risk of overall cancer (hazard ratio=0.71; 95% CI 0.59-0.85; p<0.001). About half of the observed cancers were female-specific, and the incidence of these were lower in the surgery group compared with the control group (hazard ratio=0.68; 95% CI 0.52-0·88; p=0.004). The surgical treatment benefit with respect to female-specific cancer was significantly associated with baseline serum insulin (interaction p value=0.022), with greater relative treatment benefit in patients with medium or high insulin levels. Separate analyses of different types of female-specific cancers showed that bariatric surgery was associated with reduced risk of endometrial cancer (hazard ratio=0.56: 95% CI 0.35-0.89; p=0.014).Conclusions In this long-term study, bariatric surgery was associated with reduced risk of female-specific cancer, especially in women with hyperinsulinemia at baseline.Funding This project was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R01DK105948 (the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health), the Swedish Research Council K2013-99X-22279-01, K2013-54X-11285-19, Sahlgrenska University Hospital ALF research grant and Swedish Diabetes Foundation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2017.02.036

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Multiple studies have shown that MBS reduces the risk of developing cancer in the population with class II/III obesity, ranging from 11% to 50% for all cancer types.

    “Multiple studies have shown that MBS reduces the risk of developing cancer in the population with class II/III obesity, ranging from 11% to 50% for all cancer types [130, 134–137].”

    From 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery (2023) · cites this paper as [136]

    The Results (page unavailable) report an overall-cancer hazard ratio of 0.71 after bariatric surgery, a 29% lower risk within the claimed 11%–50% range. The Methods (page unavailable) specify women aged 37–60 with BMI >38 kg/m², and the Introduction says the earlier SOS finding showed a reduction in women but not men. This paper therefore supports one result within the range, not the range itself or a reduction across the whole class II/III obesity population. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 29 · Cited by 134

Authors
Anveden, Å., Taube, M., Peltonen, M., Jacobson, P., Andersson-Assarsson, J. C., Sjöholm, K., Svensson, P.-A., & Carlsson, L. M. S.
Affiliations
  • Hallands sjukhus Halmstad (SE)
  • University of Gothenburg (SE)
  • Finnish Institute for Health and Welfare (FI)
Corresponding author
Svensson, Per-Arne
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2017-05
Volume
145
Issue
2
Pages
224-229
ISSN
0090-8258 (ISSN-L)
OpenAlex
W2593114847
Cited by
134
References
29
Citations by year
2026: 12 · 2025: 9 · 2024: 12 · 2023: 12 · 2022: 20 · 2021: 17 · 2020: 18 · 2019: 13 · 2018: 15 · 2017: 6
FWCI
14.56
Type
journal article
Language
en
Open access
Locations
  • Gynecologic Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK105948)
  • Swedish Research Council (K2013-54X-11285-19)
  • Sahlgrenska University Hospital (ALFGBG-428911, ALFGBG-429711, ALFGBG-69491)
  • Swedish Diabetes Foundation (DIA2016-139)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
Keywords
bariatric surgery, women's cancer, obesity, endometrial cancer, hyperinsulinemia, serum insulin, cancer incidence, long-term outcomes, women
MeSH terms
Adult, Female, Follow-Up Studies, Genital Neoplasms, Female, Humans, Hyperinsulinism, Middle Aged, Obesity, Prospective Studies, Registries, Sweden, Cohort Studies, Incidence, Case-Control Studies, Endometrial Neoplasms, Bariatric Surgery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review